Lubiprostone Does Not Affect Serum Electrolytes and Markers of Renal Function in Patients With Irritable Bowel Syndrome With Constipation

被引：0

作者：

Rao, Satish ^{[1
]}

Johanson, John ^{[2
]}

Spierings, Egilius ^{[3
,4
,5
]}

Lichtlen, Peter ^{[6
]}

Habibi, Sepideh ^{[7
]}

机构：

[1] Georgia Regents Univ, Augusta, GA USA

[2] Univ Illinois, Coll Med, Rockford, IL 61107 USA

[3] Tufts Univ, Sch Dent Med, Craniofacial Pain Ctr, Boston, MA 02111 USA

[4] Tufts Med Ctr, Headache & Face Pain Program, Dept Neurol, Boston, MA USA

[5] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA

[6] Sucampo AG, Zug, Switzerland

[7] Sucampo Pharma Amer LLC, Bethesda, MD USA

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2014年 / 109卷

关键词：

D O I：

10.14309/00000434-201410002-01812

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1812

引用

页码：S536 / S536

页数：1

共 50 条

[21] Effects of Baseline Abdominal Pain on Response to Lubiprostone in Patients With Constipation-Predominant Irritable Bowel Syndrome
Chang, Lin
Chey, William D.
Drossman, Douglas A.
Losch-Beridon, Taryn R.
Wang, Martin
Lichtlen, Peter
Mareya, Shadreck M.
GASTROENTEROLOGY, 2015, 148 (04) : S653 - S653
[22] Irritable bowel syndrome and chronic constipation in patients with endometriosis
Meurs-Szojda, M. M.
Mijatovic, V.
Felt-Bersma, R. J. F.
Hompes, P. G. A.
COLORECTAL DISEASE, 2011, 13 (01) : 67 - 71
[23] Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome
Raschi, Emanuel
De Ponti, Fabrizio
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2014, 10 (02) : 293 - 305
[24] Patient Response to Lubiprostone for the Treatment of Moderate to Severe Irritable Bowel Syndrome With Constipation (IBS-C)
Joswick, Taryn R.
Woldegeorgis, Fasil
Ueno, Ryuji
GASTROENTEROLOGY, 2012, 142 (05) : S449 - S449
[25] Amitiza - Lubiprostone - SUCAMPO/TAKEDA - Chloride channel activator approved for the treatment of irritable bowel syndrome with constipation
不详
FORMULARY, 2008, 43 (06) : 188 - +
[26] Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome
Lunsford, Tisha N.
Harris, Lucinda A.
INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2010, 2 : 361 - 374
[27] Lubiprostone is effective and well tolerated through 48 weeks of treatment in adults with irritable bowel syndrome and constipation
Chey, William D.
Drossman, Douglas A.
Scott, Charles
Panas, Raymond M.
Ueno, Ryuji
GASTROENTEROLOGY, 2008, 134 (04) : A215 - A215
[28] PAINFUL CONSTIPATION: ABDOMINAL PAIN IN PATIENTS WITH IRRITABLE BOWEL SYNDROME AND IN PATIENTS WITH FUNCTIONAL CONSTIPATION
Bouchoucha, Michel
Sportes, Adrien
Mary, Florence
Bon, Cyriaque
Sabate, Jean-Marc
Benamouzig, Robert
GASTROENTEROLOGY, 2017, 152 (05) : S514 - S514
[29] Patients with irritable bowel syndrome and constipation are more depressed than patients with functional constipation
Bouchoucha, Michel
Hejnar, Maria
Devroede, Ghislain
Boubaya, Marouane
Bon, Cyriaque
Benamouzig, Robert
DIGESTIVE AND LIVER DISEASE, 2014, 46 (03) : 213 - 218
[30] WHY PATIENTS WITH CHRONIC CONSTIPATION OR IRRITABLE BOWEL SYNDROME WITH CONSTIPATION ARE NOT SATISFIED WITH THERAPY?
Basilisco, Guido
Barbara, Giovanni
Bellini, Massimo
Cataudella, Giovanni
D'Alba, Lucia
Guarino, Michele Pier Luca
Iovino, Paola
Neri, Maria C.
Sarnelli, Giovanni
Savarino, Edoardo V.
Tolone, Salvatore
Torresan, Francesco
Usai-Satta, Paolo
Lovati, Ambra E.
Arsie, Elena
Coletta, Marina
GASTROENTEROLOGY, 2019, 156 (06) : S597 - S598

← 1 2 3 4 5 →